NCT01845428View on ClinicalTrials.gov

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Nephrotic SyndromeHyperlipidemia
Interventions
DRUG

Pravastatin

After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.

Trial Locations (1)

27599-7155

Unc Kidney Center, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT01845428 - Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome | Biotech Hunter | Biotech Hunter